These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 15017493)

  • 21. An investigation of the effect of immediate and extended release venlafaxine on nocturnal melatonin and cortisol release in healthy adult volunteers.
    Hallam KT; Begg DP; Olver JS; Norman TR
    Hum Psychopharmacol; 2008 Mar; 23(2):129-37. PubMed ID: 18172907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of buspirone on gastric sensorimotor function in man.
    Van Oudenhove L; Kindt S; Vos R; Coulie B; Tack J
    Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1326-33. PubMed ID: 18793342
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder.
    Aldosary F; Norris S; Tremblay P; James JS; Ritchie JC; Blier P
    Int J Neuropsychopharmacol; 2022 Apr; 25(4):283-292. PubMed ID: 34958348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venlafaxine extended-release for depression following spinal cord injury: a randomized clinical trial.
    Fann JR; Bombardier CH; Richards JS; Wilson CS; Heinemann AW; Warren AM; Brooks L; McCullumsmith CB; Temkin NR; Warms C; Tate DG;
    JAMA Psychiatry; 2015 Mar; 72(3):247-58. PubMed ID: 25607727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.
    Gelenberg AJ; Lydiard RB; Rudolph RL; Aguiar L; Haskins JT; Salinas E
    JAMA; 2000 Jun; 283(23):3082-8. PubMed ID: 10865302
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of venlafaxine on cortical motor area activity in healthy subjects: a pilot study.
    Li CY; Song XZ; Han LX; Xie Q; Wang J; Li YK; Liu FD; Liu Y
    J Clin Psychopharmacol; 2014 Feb; 34(1):93-8. PubMed ID: 24317453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Venlafaxine: a 2003 update.
    Gutierrez MA; Stimmel GL; Aiso JY
    Clin Ther; 2003 Aug; 25(8):2138-54. PubMed ID: 14512125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafaxine: I. in vivo electrophysiological studies in the rat.
    Béïque J; de Montigny C; Blier P; Debonnel G
    Neuropharmacology; 2000 Jul; 39(10):1800-12. PubMed ID: 10884561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors.
    Rudolph RL
    Acta Psychiatr Scand Suppl; 2002; (415):24-30. PubMed ID: 12492770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Venlafaxine marketed as antidepressant.
    Am J Hosp Pharm; 1994 Jul; 51(13):1606. PubMed ID: 7942885
    [No Abstract]   [Full Text] [Related]  

  • 31. Specific effect of venlafaxine on single and repetitive experimental painful stimuli in humans.
    Enggaard TP; Klitgaard NA; Gram LF; Arendt-Nielsen L; Sindrup SH
    Clin Pharmacol Ther; 2001 Apr; 69(4):245-51. PubMed ID: 11309553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K; Gee MD; Krishen A; Wunderlich HP; Le Clus A; Evoniuk G; Modell JG
    J Psychopharmacol; 2010 Aug; 24(8):1209-16. PubMed ID: 19939870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients.
    Feighner JP; Entsuah AR; McPherson MK
    J Affect Disord; 1998 Jan; 47(1-3):55-62. PubMed ID: 9476744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo.
    Shelton C; Entsuah R; Padmanabhan SK; Vinall PE
    Int Clin Psychopharmacol; 2005 Jul; 20(4):233-8. PubMed ID: 15933485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of serotonin in the control of esophageal sensitivity assessed by multimodal stimulation in health.
    Broers C; Geeraerts A; Boecxstaens V; Van Houtte B; Geysen H; Peersman N; Vermeersch P; Vanuytsel T; Tack J; Pauwels A
    Neurogastroenterol Motil; 2021 Mar; 33(3):e14057. PubMed ID: 33280212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression.
    Rudolph RL; Feiger AD
    J Affect Disord; 1999 Dec; 56(2-3):171-81. PubMed ID: 10701474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of serotonin/norepinephrine reuptake inhibitors and serotonin receptor agonist on morphine analgesia and tolerance in rats.
    Ozdemir E; Gursoy S; Bagcivan I
    J Physiol Sci; 2012 Jul; 62(4):317-23. PubMed ID: 22544464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release.
    Rickels K; Etemad B; Khalid-Khan S; Lohoff FW; Rynn MA; Gallop RJ
    Arch Gen Psychiatry; 2010 Dec; 67(12):1274-81. PubMed ID: 21135327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clarification of venlafaxine chemistry, pharmacology, and pharmacokinetics.
    Albano D; Amchin J
    Am J Health Syst Pharm; 1995 Jul; 52(14):1573-4. PubMed ID: 7552908
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of venlafaxine in the sleep architecture of rats.
    Salin-Pascual RJ; Moro-Lopez ML
    Psychopharmacology (Berl); 1997 Feb; 129(3):295-6. PubMed ID: 9084070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.